Cambridge Enterprise Ventures a finalist in this year’s UK Business Angels Association’s Investment Awards

The nomination is a recognition for the work of the team as it invests in and supports ventures spinning out of the University of Cambridge, helping bridge the gap between research and commercial opportunity.

Through investment, expertise and collaboration, the Ventures team works with researchers, founders and partners to help companies grow, contributing to companies that are scaling internationally and delivering meaningful outcomes.

Christine Martin, Head of Cambridge Enterprise Ventures, commented:

“Being recognised as a finalist for Seed VC of the Year reflects the strength of our portfolio and the achievements of the companies we support.”

A proven track record of growth and impact

Over the past 30 years, Cambridge Enterprise Ventures has supported the development of more than 210 University-connected companies.

Today, our portfolio includes over 120 companies spanning sectors including life sciences, healthcare, AI, quantum technologies and sustainability. This reflects both the breadth of innovation emerging from Cambridge and the diverse challenges these ventures are tackling.

As these companies have grown, they have attracted more than £3.5 billion in follow-on funding from investors around the world. Alongside this growth, the Ventures portfolio has delivered more than 60 full and partial exits, generating returns that can be reinvested into the next generation of Cambridge innovation.

Portfolio success in action

The figures tell one part of the story. Behind them are companies building on Cambridge research to develop technologies that tackle major global challenges. Three recent examples include:

These companies represent the latest generation of ventures emerging from the University, building on a much longer history of success. Over the past three decades, Cambridge Enterprise Ventures has supported companies that have gone on to achieve significant commercial milestones through acquisitions, public listings and international growth.

Notable examples include Solexa, whose sequencing technology helped transform genomics, Cambridge Display Technology, a pioneer in polymer OLED display technology, and more recent successes such as Gyroscope Therapeutics and Centessa Pharmaceuticals. Together, these examples demonstrate the long-term value that can emerge from University-connected innovation.

Working together to scale innovation

The success of Cambridge Enterprise Ventures is built on more than investment alone. Our team works alongside academics, founders, investors and partners to help ventures access the expertise, networks and funding needed to grow.

We focus on areas where Cambridge research and innovation can address major global challenges, with our portfolio clustered into four areas of activity: Life Science, Physical Science, Sustainability and Social Venturing. Many of these ventures also align strongly with the UK Government’s Industrial Strategy growth-driving sectors, highlighting the contribution Cambridge innovation can make to the UK’s future economic growth.

By combining focused investment with deep expertise and long-term collaboration, we help founders navigate the journey from early-stage idea to scalable business, strengthening both the Cambridge ecosystem and the wider innovation economy.

Looking ahead

Over the past 30 years, Cambridge Enterprise Ventures has supported companies addressing challenges across healthcare, sustainability, advanced technologies and beyond. As new discoveries emerge from the University, the opportunity to create economic and societal impact through venture creation continues to grow.

Congratulations to all of this year’s finalists and thank you to UKBAA for hosting a fantastic evening celebrating angel investment and innovation.

Explore our portfolio and discover more of the ventures shaping the future.